跳至主要内容
临床试验/NCT03815929
NCT03815929已完成2 期

Impact of Individualized Estrogen Therapy on Cardiovascular Disease Risk Parameters in Young Women After Bilateral Oophorectomy: A Randomized Controlled Trial

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2019年3月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Mayo Clinic
入组人数
35
试验地点
1
主要终点
Arterial Stiffness

研究概览

简要总结

Researchers are trying to assess the appropriate dose of estrogen for decreasing the risk of cardiovascular disease in women who have removal of their ovaries at a young age, before the age of 46 years.

详细描述

Baseline Study Visit: Subjects will report for the Baseline Study Day in an 8 hour fasting state (water only) and refrain from heavy exercise, caffeine, and alcohol for 24 hours. The participant will undergo study specific procedures including a urine pregnancy test if they are of child bearing potential. Participants will also complete a set of questionnaires. After the completion of the study tests, participants will be offered a meal.

Participants scheduled for surgery to remove their ovaries: after the surgery subjects will be randomized to one of two groups. They will receive the standard dose of the hormone (estrogen) patch, generally prescribed to patients after removal both ovaries. Or sent home on the standard dose hormone patch, hormone levels will be tested every 3-4 weeks, and patch dose adjusted until the estrogen level is reached that results in the hormone levels of a young woman before menopause. In order to check hormones, subjects will be able to choose to have a lab kit sent to them and have the draw done locally, or can come in person.

Participants will also receive a second hormone prescription if they have an intact uterus to protect the lining of the uterus from the effects of using estrogen alone.

6-Month Study Visit: Subjects will be asked to come back and repeat most of the study specific tests from the baseline study visit that will take about 5 hours.

1-Year Study Visit: Subjects will be asked to come back for the final visit and will repeat all the study tests done at baseline visit. This visit will take about 5 hours.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
21 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Premenopausal women undergoing (or completion of a) bilateral oophorectomy for non-malignant diagnoses at Mayo Clinic, Rochester; or premenopausal women not undergoing the procedure for the timed control group
  • Currently between the ages of 21- 45 years
  • Able to participate fully in all aspects of the study
  • Able to understand and sign the informed consent.

排除标准

  • History of hepatic, renal, or hematological diseases
  • History of venous thromboembolism; peripheral vascular disease; coronary artery disease; stroke/neurovascular disease
  • Chemotherapy or radiation therapy in the preceding 3 months
  • Current tobacco use
  • Current use of medication that alters autonomic or vascular function (e.g. tricyclic antidepressants, α-blockers, β-blockers, etc.) or aromatase inhibitor/tamoxifen therapy
  • Contra-indication to estrogen use
  • Current or previous diagnosis of breast and endometrial cancer
  • For Timed Controls: Are currently pregnant or lactating, or are of child-bearing potential or are likely to become pregnant during the study and unwilling to use contraception; Acceptable forms include:Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm), Copper Intra Uterine Device, Hysterectomy, Tubal ligation, Abstinence (no sex)
  • Any condition or factor judged by the investigator to preclude participation in the study

研究组 & 干预措施

Standard replacement therapy regimen

Active Comparator

100 mcg transdermal estradiol patch (or equivalent oral dose)

干预措施: Estradiol 100 Micrograms Patch (Drug)

Titrated replacement therapy regimen

Active Comparator

Transdermal estradiol patch (or equivalent oral dose) titrated to achieve pre-menopausal estradiol level

干预措施: Estradiol Patch (Drug)

结局指标

主要结局

Arterial Stiffness

时间窗: Baseline, 6 months, and 12 months

Augmented pressure, a measure of arterial stiffness was recorded through high-fidelity pressure waveforms and compared at planned time frames

次要结局

  • Mean Blood Pressure Reactivity to Isometric Hand Grip Exercise(Baseline, 6 months, and 12 months)
  • Mean Blood Pressure Reactivity to Cold Stress(Baseline, 6 months, and 12 months)
  • Changes in Whole Body Fat(Baseline and 12 months)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ekta Kapoor

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验

已完成
3 期
The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.Heart Disease
NCT03097120Wake Forest University Health Sciences309
已完成
不适用
Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast CancerAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8PremenopausalPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8
NCT03505736Wake Forest University Health Sciences25
已完成
2 期
EPAT: Estrogen in the Prevention of Atherosclerosis TrialPostmenopauseAtherosclerosis
NCT00115024National Institute on Aging (NIA)222
已完成
2 期
Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal WomenPostmenopauseHypercholesterolemia
NCT00001752National Heart, Lung, and Blood Institute (NHLBI)30
已完成
不适用
Effects of Gender-Affirming Hormone Therapy Among Transgender WomenTransgender WomenHIV/AIDSCardiovascular DiseasesMetabolic DiseaseCoagulopathy
NCT04128488Massachusetts General Hospital33